FREEDOM with FFR: Different Outcomes?

The FREEDOM has clearly established the benefit of myocardial revascularization surgery (CABG) over percutaneous coronary intervention (PCI) in diabetic patients with multivessel disease. Coronary physiology as guideline for revascularization works best precisely in this kind of patients and its impact has never been studied in diabetics. 

El estudio FREEDOM con FFR ¿Cuál hubiera sido su resultado?

This study, published in Circ Cardiovasc Interv, assessed the long-term outcomes of FFR guided PCI vs. CABG in diabetic patients with multivessel disease. 

Between 2010 and 2018 it included 4622 diabetic patients receiving a coronary angiogram for the purpose of this study. Inclusion criteria included the presence of at least 2 vessels with >50% diameter stenosis, where at least one intermediate lesion (30 to 70% diameter stenosis) was deferred thanks to FFR. Primary end point was a combination of all cause death, MI, revascularization, and stroke. 

Finally, 209 patients undergoing surgery and 209 undergoing FFR guided PCI were included.

Primary end point rate at 5 years resulted significantly higher in the FFR guided PCI group (44.5% vs 31.9%; HR, 1.60 CI 95%, 1.15–2.22; p=0.005). This difference was driven mainly by repeat revascularization (24.9% vs 8.2%; HR 3.51 CI 95%, 1.93 to 6.40; p<0.001).


Read also: More Evidence for Short Term DAPT: Approaching “the Class Effect”.


If we only take death, MI or stroke into account, the outcome is practically the same (28.8% vs 27.5%; HR, 1.05 CI 95%, 0.72 to 1.53; p=0.81).

This differs from the FREEDOM outcomes, where at 3.8 years there was a significant difference in mortality in favor of surgery. 

Conclusion

Diabetic patients with multivessel disease benefit from surgery at the expense of a lower revascularization rate compared against FFR guided PCI. 

At 5 years, there were no significant differences in the “hard” combined end point of all cause death, MI or stroke between CABG and FFR guided PCI. 

Original Title: Coronary Artery Bypass Grafting or Fractional Flow Reserve–Guided Percutaneous Coronary Intervention in Diabetic Patients With Multivessel Disease.

Reference: Giuseppe Di Gioia et al. Circ Cardiovasc Interv. 2020;13:e009157. DOI: 10.1161/CIRCINTERVENTIONS.120.009157.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...